Document Detail


Drug-eluting balloon for the treatment of failing hemodialytic radiocephalic arteriovenous fistulas: our experience in the treatment of juxta-anastomotic stenoses.
MedLine Citation:
PMID:  24531999     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
<sec id="st1"><title>ABSTRACT</title> <bold><italic>Purpose:</italic></bold> The purpose of this article is to report our experience with drug-eluting balloons for the treatment of juxta-anastomotic stenoses of failing radiocephalic hemodialytic arteriovenous shunt and to evaluate the primary and secondary patency (PP and SP). <bold><italic>Methods:</italic></bold> After approval by the local hospital's Ethical and Scientific Review Board, 26 consecutive patients with juxta-anastomotic stenosis of radiocephalic hemodialytic shunt were treated with angioplasty with drug-eluting balloon. The main objective was to evaluate PP defined, in accordance with the Kidney Disease Outcomes Quality Initiative recommendation, as the absence of dysfunction of the vascular access, patent lesion or residual stenosis <30% and no need for further reintervention of the target lesion (TL). PP and SP at 6, 12 and 24 months were evaluated, with echo color doppler and phlebography, for both arteriovenous fistulae, defined as absolute, and TL. <bold><italic>Results:</italic></bold> Immediate postprocedural technical and clinical success was 100% for all the patients; we had only one technical failure in repeated treatments. At 6 months the absolute and TL PP was 96.1%; at 12 months the absolute PP was 81.8%, TL PP 90.9%, absolute SP 95.4%, TL SP 100%; at 24 months the absolute and TL PP was 57.8%; absolute and TL SP 94.7%; only one arteriovenous fistula was lost during the period. <bold><italic>Conclusions:</italic></bold> The use of drug-eluting balloons, after standard angioplasty, improves primary patency and decreases reinterventions of TL in juxta-anastomotic stenoses of failing native dialytic arteriovenous shunts. </sec>
Authors:
Domenico Patanè; Stefania Giuffrida; Walter Morale; Giuseppe L'anfusa; Daniela Puliatti; Paola Bisceglie; Giuseppe Seminara; Giacomo Calcara; Domenico Di Landro; Pierantonio Malfa
Related Documents :
25007689 - Comparative hemodynamic advantages of subarachnoid administration of atypical and non-a...
21091329 - Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by p...
24710919 - Switching to an etravirine-containing regimen due to drug intolerance in clinical pract...
23953179 - One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitaz...
23315429 - Propionyl-l-carnitine versus pentoxifylline : improvement in walking capacity in patien...
11249229 - Where there's hope.
21764609 - Stem-cell therapy for peripheral arterial occlusive disease.
17924829 - Cysltr1 promoter polymorphism and requirement for leukotriene receptor antagonist in as...
1546349 - Continuous subcutaneous terbutaline pump therapy for premature labor: safety and efficacy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-2-10
Journal Detail:
Title:  The journal of vascular access     Volume:  0     ISSN:  1724-6032     ISO Abbreviation:  J Vasc Access     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2014-2-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100940729     Medline TA:  J Vasc Access     Country:  -    
Other Details:
Languages:  ENG     Pagination:  0     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of FLIXENE™ and standard PTFE arteriovenous graft for early haemodialysis.
Next Document:  The use of tunneled central venous catheters: inevitable or system failure?